Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Ana Paula Jesus-NunesGustavo C LealFernanda S Correia-MeloFlávia VieiraRodrigo P MelloAna Teresa Caliman-FontesMariana V F EchegarayRoberta F MarbackLívia N F Guerreiro-CostaBreno Souza-MarquesCassio Santos-LimaLucca S SouzaIgor D BandeiraFlavio KapczinskiAcioly L T LacerdaAna Paula Jesus-NunesPublished in: Human psychopharmacology (2022)
Number of treatment failures and severity of illness were predictors of fewer remissions and responses of depressive symptoms in this TRD population. Study of predictors of remission may contribute to better selection patients that may benefit from receiving ketamine.
Keyphrases
- depressive symptoms
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- pain management
- sleep quality
- low dose
- peritoneal dialysis
- prognostic factors
- disease activity
- ulcerative colitis
- social support
- systemic lupus erythematosus
- patient reported outcomes
- chronic pain
- replacement therapy